Objectives: To assess the prevalence of resistance to rilpivirine and mutations at position 138 in reverse transcriptase and to identify associated epidemiological and biological characteristics.
Introduction
Thirty years after the discovery of HIV, combined antiretroviral therapy (cART) has strongly improved patients' prognosis, thus leading to a high percentage of therapeutic success. However, the constant emergence of drug-resistant viruses remains a serious issue leading to virological treatment failures.
In addition to a variable R5/X4 HIV tropism, reduced efficacy of cART is due to mutations located in the four main HIV genes: reverse transcriptase (RT), protease, integrase and fusion protein genes. These mutations occur spontaneously because of the poor fidelity of HIV RT and can favour replication of the variant strain under treatment pressure. 1 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) currently represent the major components of cART. Nevirapine and efavirenz were the first NNRTIs available in France and were widely used because of their high potency and relatively safe profile on lipid metabolism compared with the protease inhibitors (PIs).
These molecules inhibit HIV-1 RT in a very selective but noncompetitive way, by settling in a hydrophobic pocket next to the catalytic site of RT. Binding of the NNRTI to the hydrophobic pocket leads to allosteric changes that decrease the affinity of nucleotides for the enzyme and prevent RNA reverse transcription and viral replication.
Two of the main drawbacks of nevirapine and efavirenz are their low barrier to resistance and the high degree of cross-resistance between them. 2, 3 Recent French data showed that about 5% of treatment-naive patients are infected by viral strains with primary resistance to first-generation NNRTIs. 4 In addition, potential side effects of nevirapine and efavirenz (mild to severe exanthema, CNS disorders and hepatic toxicity) also require close supervision during the first months of treatment. 5 -7 Second-generation NNRTIs developed in recent years, etravirine and then rilpivirine, which belong to the subgroup of diarylpyrimidines, are characterized by a good safety profile and a broader spectrum of activity, allowing them to be effective even on viruses resistant to first-generation NNRTIs. 3, 8, 9 This spectrum of resistance is explained by the singular chemical structure of diarylpyrimidines (in a 'horseshoe' shape) that confers much flexibility, allowing numerous conformational adaptations (by repositioning or rotation) even in viruses resistant to first-generation NNRTIs.
Rilpivirine resistance-associated mutations (RAMs) were described in the ECHO and THRIVE Phase III studies by analysing the HIV-1 strains from patients experiencing virological failure under rilpivirine therapy.
10,11
To date, the ANRS algorithm (v23) has described 22 rilpivirine RAMs, including 17 major mutations (K101E/P, E138A/G/K/Q/R/S, V179L, Y181C/I/V, Y188L, H221Y and M230I/L/V) and 5 minor mutations (L100I, K103N/R/S and V179D).
Mutations at position 138 in RT are responsible for high-level resistance to rilpivirine because the salt bridge between the anionic Glu138 and the cationic Lys101 of the RT is crucial for the correct binding of rilpivirine to RT. The replacement of Glu138 by a cationic amino acid (e.g. a lysine, E138K mutation) breaks the salt bridge. Two positively charged amino acids, 138 and 101, tend to repel and deform the hydrophobic pocket in which rilpivirine normally comes to settle. The decreased stability of the link between rilpivirine and the RT leads to viral resistance to rilpivirine. 12, 13 Virological data from the ECHO and THRIVE Phase III studies revealed a low prevalence of rilpivirine resistance in treatmentnaive patients. 14 The main objective of the work presented here was to estimate both the prevalence of resistance to rilpivirine and E138A mutations in two groups of HIV-infected patients monitored in our Infectious Diseases department: new HIVpositive patients detected between 2011 and 2013; and existing patients showing a virological failure during this period. We also investigated the epidemiological and biological characteristics associated with resistance to rilpivirine and emergent E138A mutations.
Patients and methods

Patients
This retrospective cross-sectional study included all the patients for whom a genotype analysis was performed in the Laboratory of Virology at the University Hospital of Nancy between 1 January 2011 and 30 June 2013. When several HIV sequencing analyses were performed for one patient, it was the first one that was considered. Thus, sequencing analyses were performed for both patients with virological failure (n ¼ 111) and patients with recent infection discovery (n ¼127).
For each included patient, epidemiological (sex, address, duration of infection, route of infection), biological (viral type and subtype, viral load, CD4 count, resistance pattern with mutations in RT and resistance to etravirine and rilpivirine) and therapeutic (past highly active antiretroviral therapy and past NNRTI treatment) data were collected. The geographical location of patients' infection was evaluated according to their place of residence, their personal history and the date of discovery of HIV infection. In accordance with the ethical guidelines of Helsinki, the study was carried out on a sample collection performed in the context of classical viroclinical follow-up by physicians who care for patients suffering from HIV infection. The physicians informed their patients that remaining blood sample volumes could be used for research on HIV treatment and checked for verbal non-opposition from their patients.
Virological analyses
Plasma HIV-1 viral load was quantified using the COBAS w AmpliPrep/ COBAS w TaqMan w HIV-1 Test (Roche, threshold 20 copies/mL). Resistance mutations on the RT gene were determined using the TRUGENE HIV-1 Genotyping Assay (Siemens).
Resistances to antiretroviral drugs were determined using the ANRS algorithm (version 23, 2013, hivfrenchdrugresistance.org). Mutations Jeulin et al.
L100I+K103N/S and L100I+K103R+V179D were associated with resistance to rilpivirine. Mutations E138K, Y181V, Y181C+H221Y and a combination of at least four mutations among V90I, A98G, L100I, K101E/H/I/P/R, V106I, V179D/F/I/L/M/T, Y181C/I, G190A/S and M230L were associated with resistance to etravirine.
Phylogenetic analyses
Nucleotide and amino acid sequences of the RT gene from naive patients and patients resistant to rilpivirine were compared using MEGA 5.2 software. Phylogenetic analyses were based on the Neighbour Joining and Kimura 2 methods.
Statistics
Descriptive statistics were used to analyse patient characteristics. Quantitative variables are presented as medians and IQRs, and qualitative variables are presented as numbers and percentages.
To assess the associations between patient characteristics and resistance to rilpivirine and to E138A or other mutations, x 2 or Fisher tests were used. To assess the evolution of E138A or resistance to rilpivirine prevalence over time, x 2 or Fisher tests were used.
Results
Patient characteristics
The study included 238 patients infected with HIV-1 with available viral genomic sequencing. When multiple viral sequences were performed for the same patient, the first one was included in the current statistical analysis. Biological, epidemiological and therapeutic data appear in Table 1 . Most patients were infected in the Lorraine region (northeastern France): 125 were infected in the Meurthe-et-Moselle department (Nancy district, in the Lorraine region), 64 in the Lorraine region excluding the Meurthe-et-Moselle department and 18 in France outside of the Lorraine region ( Figure 1) . The other 31 patients were supposed to have been infected in other countries, i.e. Africa, the Caribbean, Luxembourg, Dominican Republic, Russia, Chechnya, Germany and Moldova.
Among previously treated patients (111/238, 46.6%), 68/111 (61.3%) had received NNRTIs, including 23 (33.8%) who had received nevirapine, 23 (33.8%) who had received efavirenz and 1 (1.5%) who had received etravirine. Twenty (29.4%) had received a combination of two or three NNRTIs. None had received rilpivirine.
Prevalence of rilpivirine resistance
The prevalence of rilpivirine resistance in the whole cohort was 12.6% (30/238), and was 10.2% (13/127) and 15.3% (17/111) in naive and pre-treated patients, respectively. It was significantly more frequent after treatment with efavirenz (P ¼ 0.012; Table 2) or nevirapine (P ¼ 0.0027; Table 2 ), and with increased duration of HIV infection (P ¼ 0.0226; Table 2 ). It did not tend to vary over time (Table 3) . HIV genotype B seems to be associated with resistance to rilpivirine (P ¼ 0.0005; Table 2 ). One female patient pre-treated without NNRTIs was resistant to rilpivirine (L100I + K103N).
Prevalence of the E138A mutation
The E138A mutation was the most frequent one associated with resistance to rilpivirine in the whole cohort (P,0.0001; Table 2 ). Patients with the E138A mutation were more often naive than patients without E138A mutation, (P ¼ 0.0513; Table 4 ). In 78.6% of naive patients (11/14), the E138A mutation alone was responsible for rilpivirine resistance. In pre-treated patients, Unexpected prevalence of E138A-associated rilpivirine resistance 3097 JAC Y181C was mainly involved in rilpivirine resistance (n ¼ 8).
However, for three patients showing virological failure under an NNRTI regimen, only the E138A mutation was highlighted. The median (Q1 -Q3) duration of HIV infection tended to be shorter in E138A patients than in other patients [0 (0 -6) years versus 2 (0 -14) years], although this was not significant. Figure 2 shows the prevalence of the different rilpivirine RAMs. The E138A mutation was not associated with the presence of other rilpivirine-related mutations (¼ 0.607; Table 4 ). Moreover, the E138A mutation was found exclusively as a unique mutation, in the absence of other rilpivirine RAMs. These other rilpivirine RAMs were significantly correlated with previous NNRTI-based treatment of any kind (P, 0.002). The prevalence of the E138A mutation tended to increase over time, from 3.6% (2/55) during the first half of 2011 to 9.3% (4/43) during the first half of 2013 (P ¼ 0.0614; Table 3 ).
Epidemiological characteristics and phylogenetic analyses
In our study, we observed a high incidence of the E138A mutation increasing over the 2 year period. This involved mainly naive patients who were recently diagnosed (n¼ 11). The naive patients (n¼ 127) were mostly men (n ¼95), especially those who had sex with men (n¼ 58). The hypothesis of a resistant strain emergence was evaluated by phylogenetic analyses of the HIV RT gene.
All HIV strains from naive patients and/or viral strains resistant to rilpivirine were analysed for the RT gene. A predominant cluster of 29 strains including seven naive E138A-positive patients was observed ( Figure S1 , available as Supplementary data at JAC Online). The 25 HIV strains from naive patients of this cluster were analysed independently from amino acid sequences (Figure 3) . Seven viral strains from seven male patients infected with a subtype B virus and positive for the E138A mutation appeared according to two subgroups within the same cluster (of five and two patients, respectively; Figure 3 ); all were supposed to have been infected in the Lorraine region and four of them reported having sex with men. According to phylogenic analyses, the three other naive male patients showing the E138A mutation were infected by strains that were distant from the previous cluster and distant from each other.
Discussion
Rilpivirine is a recent second-generation NNRTI available in France since 2012 and recommended for naive patients whose viral load is ,100 000 copies/mL. Its main biological advantage is its efficacy against most viral strains resistant to first-generation Jeulin et al.
NNRTIs. Within the concept of 'treatment as prevention', recommendations for the management of HIV-infected patients are in favour of early cART initiation after diagnosis. 15 As a consequence, prescriptions for rilpivirine are expected to increase in the coming years.
In addition, this molecule is available as a single-tablet regimen, and has a good safety profile and a broader activity spectrum than the first-generation NNRTIs (being effective against K103N mutated viruses). For this reason, it has also been proposed for use in pre-treated patients, although this is not yet recommended. 16 However, the low genetic barrier for rilpivirine resistance has now been well demonstrated. Even in patients with a low baseline viral load (,100000 copies/mL), the ECHO and THRIVE Phase III trials demonstrated that virological failure under a rilpivirine regimen occurred in 8% of cases, of which 37% were due to NNRTI RAMs.
11 Thus precautions must be taken and prior investigation for rilpivirine RAMs by bulk sequencing is widely recommended before rilpivirine initiation, in either naive or previously treated patients.
Due to recent marketing of rilpivirine, partial data concerning resistance to it in France are available. In naive patients, with all Unexpected prevalence of E138A-associated rilpivirine resistance 3099 JAC subtypes, primary resistance to rilpivirine was described to be 4.9% using bulk sequencing, 17 compared with 10.2% in our cohort. In both studies, E138A was the most frequent rilpivirine RAM, isolated in 3% of naive patients compared with 8.7% in our cohort. Therefore, the prevalence of rilpivirine resistance and E138A mutation seems to be higher in our cohort than in previously published French data, including patients followed in two French regions (Paris and Bordeaux) outside the Lorraine region, while the ECHO and THRIVE studies revealed a low prevalence of rilpivirine resistance in treatment-naive patients (2.7%). 14 Moreover, in our study the prevalence of E138A mutation strongly increased over time, reaching 12.8% in the second half of 2012.
Concerning pre-treated patients, rilpivirine resistance reached 15.4% and was associated with previous treatment with efavirenz (P ¼ 0.012) or nevirapine (P ¼ 0.027). These results are similar to data from Anta et al., 20 who reported a resistance rate of 19.3% in patients with virological failure under an NNRTI regimen (efavirenz, nevirapine or etravirine). In that study, the most frequent selected mutation was Y181C (21.8%), as described in our cohort and by Adams et al. 3 However, unlike in our study, the authors showed a higher risk of cross-resistance after a regimen including etravirine (27.6%), followed by nevirapine (25%) and then efavirenz (14.5%). Concerning E138A variants in pre-treated patients, the low prevalence found in the other study (3.9%) was consistent with our data. 18 In patients pre-treated but not with NNRTIs, the prevalence of resistance to rilpivirine (2.3%) was similar to that described by Sluis-Cremer et al., with values of 2% to 6.1%. 19 Interestingly, the E138A mutation was not more frequent in NNRTI-pre-treated patients.
Possible variations in the prevalence of rilpivirine RAMs according to viral subtypes are unclear. In our study, 102 patients infected with HIV non-B subtypes were included, with only four patients who were resistant to rilpivirine and one who was positive for E138A mutation. Genotype B seems to be associated with rilpivirine resistance, but a problem of sampling or representativeness of the sample cannot be excluded. The published data of Anta et al. 20 showed that the overall prevalence of rilpivirine resistance did not differ significantly according to the genotype, while other published data described an increased prevalence of resistance to rilpivirine in non-B subtypes (6%) compared with B subtypes (3.7%). 17 In RTI-naive patients, the Stanford University database counts 1.8%, 5.9% and 2.3% of E138A strain in subtypes B, C and CRF02_AG, respectively. Anyway, regardless of subtype (B, C or CRF02), only one nucleotide mutation (A C transversion) is needed to switch from glutamic acid to alanine at position 138 of the RT. Jeulin et al.
Major mutations currently associated with rilpivirine resistance by the ANRS algorithm are K101E/P, E138A/G/K/Q/R/S, V179L, Y181C/I/V, Y188L, H221Y and M230I/L/V, as well as five minor mutations (L100I, K103N/R/S and V179D). Mutations at residue 138 must be carefully examined in naive patients: amino acids alanine (A), lysine (K), glycine (G), glutamine (Q), arginine (R) and serine (S) have been described in place of glutamic acid (E) 138. A strong resistance is conferred by E138R mutation, while E138A corresponds to a better viral fitness. Furthermore, E138K is most frequently selected due to the mutational bias of HIV RT. 21 Recent studies have shown that both E138K and M184I frequently emerge in patients who develop a rilpivirine failure together with two nucleoside reverse transcriptase inhibitors (NRTIs; emtricitabine and tenofovir, Eviplera w , Complera w ). Phenotypic analyses showed that E138K can restore viral replication ability in the presence of M184I/V. 22 The only patient who was E138K-positive in our study, who was treatment-naive, was negative for M184V and M184I.
The exploration of minor variants conferring resistance to NNRTI by ultra-deep pyrosequencing is not currently validated for clinical practice, either for naive patients or in case of virological failure. However, some studies have demonstrated that pre-existing minor NNRTI-resistant variants are associated with virological failure and major NNRTI resistance at the time of treatment failure, 23, 24 although these results have not been confirmed by others. 25 We cannot exclude that minor E138A variants were present in our patients and were not detected by bulk sequencing. The prevalence of E138A mutations in minor strains in naive patients was evaluated to be 9%-15%. 21, 26 Elsewhere, Gatanaga et al. 27 described an increased prevalence of mutations in position E138 among naive HLA-B*18 patients compared with naive patients without HLA-B*18 (21% versus 0.37%, P, 0.01). The authors hypothesized that the selection of E138G/A/K mutations was favoured by the specific immunity pressure of HLA-B*18 patients, since amino acid 138 is a supposed epitope of HLA-B*18-restricted T cytotoxic lymphocytes. In our study the HLA-B locus was typed in 125 patients by the intermediate resolution HLA-B Luminex RSSO kit (LabType, One Lambda Inc.). The characteristics of the 125 HLA-B locustyped patients were similar to those of the whole cohort described in Table 1 . The total prevalence of HLA-B*18 patients was 11/125 (8.8%); the prevalence of HLA-B*18 patients in local blood donors is 11.7% (P. Perrier and A. Kennel, unpublished data). Consistent with data from Gatanaga et al., 27 in our study the E138A mutation was present in 2/11 (18.18%) HLA-B*18 patients versus 5/114 (4.39%) patients without HLA-B*18.
In conclusion, we observed in our centre a significantly increased resistance to rilpivirine, mostly due to the E138A mutation. Phylogenic analyses showed that E138A-positive patients were mainly men who had sex with men, diagnosed after April 2012 and infected by related HIV strains. These results support the latest international recommendations on the need for genotypic search for RAM before rilpivirine prescription in naive patients. Elsewhere, its use in NNRTI-pre-treated patients must be examined considering the high risk of cross-resistance. Taken together, our results emphasize the need to investigate the prevalence of rilpivirine RAMs in the coming years both in France and in other countries.
